Eileen Pazderka Smith, M.D.

PERSONAL DATA

Work Address:

Eastern Washington Dermatology
228 W Birch Street
Walla Walla, WA 99362
Telephone: 509-525-9404
Fax: 509-525-9433

Birth date: September 17, 1956
Birthplace: Ft. Belvior, Virginia
Citizenship: U.S.A.

EDUCATION

Baccalaureate:

• University of Nebraska Medical Center; School of Medical Technology, Omaha, Nebraska, 1974-1978. BS, Completion August 1978.

Graduate:

• University of Nebraska Medical Center; Graduate Program Medical Microbiology, Omaha, Nebraska 1982-1985. MS, Completed May 1985.
• University of Nebraska Medical Center; College of Medicine, Omaha, Nebraska 1986-1990. MD, Completed December 1990.

TRAINING

Internship:

• University of Utah School of Medicine; Internship, Department of Internal Medicine, Salt Lake City, Utah, 1990-1991, Completion, November 1991.

Fellowship:

• University of Utah School of Medicine, Research Fellowship, Division of Dermatology, Salt Lake City, Utah, 1991-1993. Completion, June 1993.

Residency:

• University of Utah School of Medicine; Dermatology Residency, Division of Dermatology, Salt Lake City, Utah, July 1993-1997. Completion, June 1997.

PROFESSIONAL EXPERIENCE

Medical Technologist 1978 –1989. Clinical microbiologist, worked in a laboratory at the University of Nebraska Medical Center in Omaha, Nebraska. I worked full time 1978 to 1986 and part time 1986 to 1989. I was responsible for the identification and sensitivity testing of clinical isolates.

Division of Disability, 1992-1994 - Employed part time in the Division of Disability in Salt Lake City, Utah. I was responsible for performing histories and physicals for disability determination.

Family Health Center, 1992-1995 - Employed part time in the urgent care center in Salt Lake City, Utah. I was responsible for diagnosis and treatment of medical illness.

Alpha Therapeutics, 1992-1995 - Employed part time in the plasma center in Salt Lake City, Utah. I was responsible for HIV and Hepatitis counseling, performing histories and physicals, and treating reactions to plasma donations.

Private Practice, 1997-2005 - Employed full time at the Walla Walla Clinic in the Department of Dermatology in Walla Walla Washington. I was responsible for diagnosis and treatment of dermatologic disease.

Solo Practice, 2006 - Present - Eastern Washington Dermatology in Dayton Washington. I am responsible for diagnosis and treatment of dermatologic disease as well as over seeing the running of the business.

RESEARCH EXPERIENCE

Masters Program - Purified the Bacillus subtilis enzyme, glucose dehydrogenase cloned in Escherichia coli for my thesis. Supervised by Harry W. McFadden, Jr., MD & Robert F. Ramaley PhD, Department of Medical Microbiology and Biochemistry; University of Nebraska Medical Center, 1982-1985.

Medical School - Studied the development of cephalosporin resistance in Enterobacter cloacae, under the supervision of Robert Ramaley PhD, Department of Biochemistry University of Nebraska Medical Center, 1987.

Medical School - Study coordinator, Temafloxacin for the Treatment of Mild to Moderate Bacterial Skin or Skin Structure Infections. The principal investigator was Ramon Fusaro MD Division of Dermatology, University of Nebraska Medical Center, 1988.

Medical School - Study coordinator, Temafloxacin versus Ciprofloxacin for the Treatment of Mild to Moderate Bacterial Skin or Skin Structure Infections. The principal investigator was Ramon Fusaro MD, Division of Dermatology, University of Nebraska Medical Center, 1989.

Research Fellow - Identified and isolated a basement membrane zone antigen reactive with IgA from sera of cicatricial pemphigoid patients under the supervision of John J. Zone, MD, Department of Dermatology, University of Utah School of Medicine, 1991-1993.

Research Fellow - Characterized a basement membrane zone antigen which was reactive with IgA from sera of cicatricial pemphigoid patients. Under the supervision of John J. Zone, MD Department of Dermatology, University of Utah School of Medicine, 1996-1997.

Clinical Investigator - Ionopheresis of Naftin for the Treatment of Onychomycosis, Principal investigator Gerry Krueger, MD Department of Dermatology, University of Utah School of Medicine, 1992.

Principle Investigator - Linezolid verus Clarithromycin for the Treatment of Uncomplicated Superficial Bacterial or Skin Structure Infections, Department of Dermatology, Walla Walla Clinic, 1997-1998.

Principle Investigator - Open-Labeled Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis, Department of Dermatology, Walla Walla Clinic, 1999-2000.

Principle Investigator - A 6 Month Randomized, Multicenter, Parallel-group, Double-blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of ASM 981 cream 1% BID vs. Standard of Care in the Management of Mild to Severe Atopic Dermatitis in Children 3 months to 11 years, Department of Dermatology, Walla Walla Clinic, 2001-2002.

Principle Investigator - A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ammonium Lactate Cream vs. Lac-Hydrin 12% Cream in Subjects with Moderate to Severe Icthyosis Vulgaris, Department of Dermatology, Walla Walla Clinic, 2001-2002.

Principle Investigator - Open-Labeled Safety Study of Tazarotene 4.5mg Capsules Once daily in patients with moderate to very severe psoriasis, Department of Dermatology, Walla Walla Clinic, 2001-2003.

Principle Investigator - Open label Trial to Evaluate the Safety and Effectiveness of Tri-Luma, in Subject with Moderate Melasma, Department of Dermatology, Walla Walla Clinic, 2003.

Principle Investigator – A Phase IIIb, Open-label, Multi-center Study to Evaluate the Safety of 1 mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoratic Therapies or have Recently Transitioned From Systemic Therapies, Department of Dermatology, Walla Walla Clinic, 2003.

Principle Investigator – A Multi-center, Open-Label Prospective Study to Evaluate the Safety of Subjects With Psoriasis Treated With Etanercept, Department of Dermatology, Walla Walla Clinic, 2004.

Principle Investigator – A Safety and Efficacy Evaluation of Tretinoin Gel, 0.05% and Vehicle, in the Treatment of Mild to Moderate Acne Vulgaris, Department of Dermatology, Walla Walla Clinic, 2005.

Principle Investigator – A Safety and Efficacy Evaluation of Adapalene gel With Other Concomitant Medication, in the Treatment of Mild to Moderate Acne Vulgaris, Department of Dermatology, Walla Walla Clinic, 2005.

Principle Investigator – A Safety and Efficacy Evaluation of Desonide gel 0.05%, In The Treatment of Mild to Moderate Atopic Dermatitis, Department of Dermatology, Walla Walla Clinic, 2005.

Principle Investigator – A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects, Department of Dermatology, Walla Walla Clinic, 2005.

Principle Investigator – APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long-Term Safety of Tacrolimus Ointment For the Treatment of Atopic Dermatitis. Eastern Washington Dermatology, 2005 - Present.

Principle Investigator – PEER: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety of Pimcrolimus Cream For the Treatment of Atopic Dermatitis, Eastern Washington Dermatology, 2005 - Present.

Principle Investigator – A Phase 3 , Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Twice Daily (BID) Tacrolimus Cream 0.1% Versus cream Vehicle in the Treatment of Psoriasis. Eastern Washington Dermatology, 2006 – 2006.

Principle Investigator – A Multi-Center, Randomized, Double-Blinded, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared with Adapalene Topical Gel, 0.1% Benzoyl Peroxide Toical Gel, 2.5% and Topical Gel Vehicle in Subjects with Acne Vulgaris. Phase III. Eastern Washington Dermatology, 2006 – 2007.

Principle Investigator – ATLAS Assessment and Tracking of Lont-Term Alefacept Safety Study. Pase IV. Eastern Washington Dermatology, 2007- 2013.

Principle Investigator – RESPONSE: Raptiva Epidemiologic Study of Psoriasis Outcomes And Safety Events In Patients With Chronic Moderate To Severe Psoriasis. Phase IV. Eastern Washington Dermatology, 2007-2011.

Principle Investigator – PSOLAR: A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Phase IV. Eastern Washington Dermatology, 2007-Present

Principle Investigator – OBSERVE 5: Observational Post-Marketing Safety Surveillance Registry of Enbrel for the Treatment of Psoriasis. Phae IV/ Eastern Washington Dermatology, 2007-2013.

Principle Investigator – SUNRISE – A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab ( REMICADE) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL). Eastern Washington Dermatology, 2007-2011.

Principle Investigator – Open Label Study to Evaluate the Efficacy and Safety of Entanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab. 2013-2014.

Principle Investigator - A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Betamethasone Dipropionate Spray 0.05% in the Treatment of Moderate Plaque Psoriasis. Eastern Washington Dermatology, 2013-2014.

Principle Investigator - A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate Plaque Psoriasis for 14 Days. Eastern Washington Dermatology, 2015-2016.

Principle Investigator - A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel(Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis. Eastern Washington Dermatology, 2015-2016.

Principle Investigator - Evaluating The Efficacy and Usage of Topical Scar Medications IN Patients with Atrophic, Keloid and Hypertrophic Scars. Eastern Washington Dermatology, 2015-2016.

Principle Investigator - A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris. Eastern Washington Dermatology, 2015-Present.

Principle Investigator - A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris. 2015-Present.

Principle Investigator - A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study to Compare the Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Subjects with Acne Vulgaris. 2015-Present.

Principle Investigator - A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety,tolerability, and efficacy in subjects with moderate to severe plaque psoriasis. 2015-Present.

PUBLICATIONS

Journals:

Zone JJ, Smith EP, Powell D, Taylor TB, Smith JB, & Meyer LJ. Antigenic Specificity of Antibodies from Patients with Linear Basement Membrane Deposition of IgA. Dermatology 189S:64-66, 1994.

Smith EP, Taylor TB, Meyer LJ, & Zone JJ. Identification of a Basement Membrane Zone Antigen Reactive with Circulating IgA Antibody in Ocular Cicatricial Pemphigoid. J Invest Dermatol 101:619-623, 1993.

Smith EP, Taylor TB, Meyer LJ, & Zone JJ. Antigen Identification in Drug Induced Bullous Pemphigoid. J Amer Acad Dermatol 29:879-82, 1993.

Smith EP & Ramaley RF. An Improved Method for the Purification of Bacillus subtilis Glucose Dehydrogenase Cloned in Escherichia coli. Preparative Biochem. 18(2):165-182, 1988.

Pazderka E. & Jones JW. Brucella abortus Endocarditis: Successful Treatment of an Infected Aortic Valve. Arch Intern Med 142:1567-1568, 1988.

Book Chapters:

Smith EP, Zone JJ: Bullous Diseases: Dermatitis Herpetiformis and Linear IgA Bullous Dermatosis. Dermatologic Clinics 11(3)511-526, 1993.

Smith EP, Fankhanel KJ, Zone JJ. Linear IgA Bullous Dermatosis. In: Clinical Dermatology, DJ Demis (ed), Lippincott-Raven, Philadelphia, 1995, Chap. 6-19, pp. 1-10.

Smith EP, Zone JJ. Linear IgA Bullous Dermatosis. In: Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. Arndt KA, LeBoit PE, Robinson JE, Wintroub B (eds.) WB Saunders Co., Philadelphia, 1996, Chap. 80, pp. 698-703.

Abstracts/Presentations:

Smith EP, Taylor TB, Meyer LJ, Zone JJ. Cicatricial Pemphigoid Antigen is Synthesized In Vitro by Human Keratinocytes. J Invest Dermatol 288:602; 1995. Poster presentation at National meeting of The Society for Investigative Dermatology, Chicago, IL, May 1995.

Smith EP, Taylor TB, Zone JJ. Circulating IgA anti-basement membrane zone antibodies in mucous membrane pemphigoid recognize two distinct basement membrane zone antigens. J Invest Dermatol 102:559, 1994. Oral presentation at the National Meeting of The Society for Investigative Dermatology, Baltimore, MD, April-May 1994.

Smith EP, Taylor TB, Meyer LJ, Zone JJ. Identification of a basement membrane zone antigen, reactive with circulating IgA antibody, in ocular cicatricial pemphigoid. Clin Res 41:472A, 1993, and J Invest Dermatol 100:575, 1993. Poster presentation at the National Meeting of The Society for Investigative Dermatology, Washington DC, April-May 1993.

Smith EP. Expression and Purification of Bacillus subtilis Glucose Dehydrogenase via Gene Cloning in Escherichia coli. The University of Nebraska Medical Center Student Research Forum, Abstract 41, 1988.

Ramaley RF, and EP Smith. Properties of Bacillus subtilis Glucose Dehydrogenase. The Fourth International Conference on Genetics and Biotechnology of Bacilli, Abstract T-18, 1987.

Pazderka E, RF Ramaley, and B Uratani. Properties of a Developmental Enzyme of Bacillus subtilis Cloned in Escherichia coli. The National Meeting of the American Society of Microbiology, Abstract K-12, 1985.

Ramaley RF, E Pazderka, and B Uratani. Properties of a Developmental Enzyme of Bacillus subtilis Cloned in Escherichia coli. The Ninth International Spores Conference, Abstract 54, 1984.

ACTIVITIES & ORGANIZATIONS

• Lambda Tau - 1974-1978
• General Diagnostic Award - 1983, 1984
• University of Nebraska Student Research Scholarship - 1987
• JM Foundation Scholarship - 1987
• Outstanding Young Women of America - 1988
• Outstanding College Students of America - 1989
• Hollis and Marjorie Limprechit Award – 1989
• Who's Who of Young Americans - 1991
• Women of the Year - 1992
• George Weber Immunology Research Foundation Grant - 1992
• Who's Who in the West - 1995
• Who's Who in Medicine and Healthcare - 1995
• Who's Who in America Women - 1996
• Dermatology Foundation Research Fellowship - 1996
• Who’s Who – 2000
• Volunteer, Indian and Chicano Health Center; 1980, 1981
• Graduate Student Council; 1984, 1985
• Nebraska Medical Association, 1986-1990
• Peer Support Group Leader, 1997
• American Medical Student Association, 1986-1990
• NMA-Medical Student Chapter, 1986-1990
• American Medical Association, 1986 to present
• AMSA Blood Drive; 1987, 1988
• AMSA Smoking Prevention Program; 1987, 1988
• Alternate to the Credentials Committee - AMA MSS, 1987
• American Medical Women's Association, 1987-1990
• Phi Ro Sigma, 1987 to present
• States Leadership Steering Committee - AMA MSS, 1988
• Chairman of publications, Residency Symposium, 1988
• Volunteer, Health Fair of the Midlands, 1988
• Rules Committee - AMA MSS, 1988
• Utah State Medical Association, 1991-1997
• Washington State Medical Association, 1997 to present
• American Academy of Dermatology, 1993 to present
• Society of Investigative Dermatology, 1993 to 1997
• Society of Nail Disorders, 1998 to 2000
• Women Dermatology Society, 1996 to 2004
• Washington State Dermatology Association 1999 to present
• Oregon Dermatology Society 1999-2004

TRAINING

• Packaging & Shipping Division 6.2 Materials April 8, 2011
• GCP Training from Quintiles May 4, 2013
• GCP Training from Novartis June 3, 2016
• Medidata Training PSOLAR June 25, 2016